Midazolam v.s. propofol for sedaion in endoscopic submucosal dissection; a randomized phase II trial. KDOG0801
Phase 2
- Conditions
- early gastric cancer, gastric adenoma
- Registration Number
- JPRN-UMIN000001497
- Lead Sponsor
- Kitasato Digestive disease and Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 138
Inclusion Criteria
Not provided
Exclusion Criteria
ASA classification:above III. severe disease in heart, lung, liver, or kidney. allergic episode with midazolam or propofol. women in pregnancy or breast-feeding any other reasosn by which docter judged inappropriate case.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the efficacy of sedation enough for endoscopic submucosal dissection.
- Secondary Outcome Measures
Name Time Method the safety of sedation during endoscopic submucosal dissection. the sagety of sadation after endoscopic submucosal dissection.